Rawcliffe Adrian sold 30,080 shares of ADAP
Form 4 filed Jan 17, 2024 · transaction dated Jan 17, 2024 · Signed by Niklas Feldmann
What happened
On Jan 17, 2024, Rawcliffe Adrian, Chief Executive Officer sold 30,080 shares of ADAP (Adaptimmune Therapeutics PLC) at $0.67 per share.
The transaction was filed under SEC Form 4 transaction code S, for a total transaction value of $20,154.
This filing made the top-scored cut on FilingIQ's multi-factor signal model, which weighs insider context (seniority, prior conviction history), trade structure (transaction code, plan status, position sizing), and market environment together. The methodology is documented at methodology. Sign up to see this trade's Score and full dimension breakdown.
The raw filing is on SEC EDGAR at https://www.sec.gov/Archives/edgar/data/1621227/000110465924004564/0001104659-24-004564-index.htm.
The accession number is 0001104659-24-004564.
Related
Methodology and sources
This page summarizes a single SEC Form 4 disclosure. The underlying XML is publicly filed by the issuer and available on SEC EDGAR at the link above. FilingIQ does not modify the underlying filing; this page is a normalized rendering with cross-references and a FilingIQ Score. Author: Niklas Feldmann. Scoring methodology: methodology. Not investment advice; see disclaimer.